Literature DB >> 8726940

Adenosine deaminase (ADA) isoenzyme analysis in pleural effusions: diagnostic role, and relevance to the origin of increased ADA in tuberculous pleurisy.

L Valdés1, E San José, D Alvarez, J M Valle.   

Abstract

The rise in adenosine deaminase (ADA) activity in the pleural fluid of tuberculous pleurisy patients, though used for diagnosis, is of unknown origin. In this work, we determined ADA activity and the activities of 2'-deoxyadenosine deaminase and ADA-2 in 350 patients. We also considered whether the results throw light on the origin of high pleural fluid ADA in tuberculous pleurisy and estimated the diagnostic efficiency of 2'-deoxyadenosine deaminase, ADA-2 and total ADA activities with and without the inclusion of the 2'-deoxyadenosine deaminase/ADA activity ratio in a combined criterion. The 350 pleural effusions were classified by previously established criteria as transudates (60 males/18 females) or as tuberculous (49 males/27 females), neoplastic (50 males/39 females), parapneumonic (36 males/19 females), empyematous (11 males/3 females), or miscellaneous (25 males/13 females) exudates. Total ADA, ADA-2 and 2'-deoxyadenosine deaminase activities were, respectively, 127.5 +/- 2.9, 103 +/- 29.5 and 42.8 +/- 14 U.L-1 in tuberculous exudates. With diagnostic thresholds of 47, 40 and 22 U.L-1 respectively, the sensitivities of ADA, ADA-2 and 2'-deoxyadenosine deaminase for tuberculosis were 100, 100 and 95%; their specificities 91, 96 and 92%; and their efficiencies 93, 97 and 93%, respectively. One hundred and one effusions (all 76 tuberculous, 12 neoplastic, 4 parapneumonic and 9 empyematous exudates) had total ADA levels > 47 U.L-1; of these, 8 neoplastic, 1 parapneumonic and all the tuberculous exudates had a 2'-deoxyadenosine deaminase/ADA activity ratio < 0.49. The criterion of simultaneously having ADA > 47 U.L-1, ADA-2 > 40 U.L-1 and a 2'-deoxyadenosine deaminase/ADA activity ratio < 0.49 was satisfied by all the tuberculous effusions but only eight others (all neoplastic) (sensitivity 100%, specificity 97%, efficiency 98%). We conclude that: 1) high total ADA activity in tuberculous pleural effusions is due mainly to an increase in ADA-2, and, therefore, originated from the only known source monocytes and macrophages; 2) ADA-2 was a more efficient diagnostic marker of tuberculous pleurisy than total ADA activity, although the difference was not statistically significant; and 3) among effusions with high total ADA the 2'-deoxyadenosine deaminase/ADA activity ratio differentiates tuberculous effusions from empyemas and parapneumonic effusions, but fails to discriminate well between tuberculous and neoplastic effusions.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8726940     DOI: 10.1183/09031936.96.09040747

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  34 in total

1.  Predominance of Th1 Immune Response in Pleural Effusion of Patients with Tuberculosis among Other Exudative Etiologies.

Authors:  Vinícius da Cunha Lisboa; Marcelo Ribeiro-Alves; Raquel da Silva Corrêa; Isabelle Ramos Lopes; Thiago Thomaz Mafort; Ana Paula Santos; Thaís Porto Amadeu; Rogério Rufino; Luciana Silva Rodrigues
Journal:  J Clin Microbiol       Date:  2019-12-23       Impact factor: 5.948

Review 2.  Tuberculous pleural effusions: advances and controversies.

Authors:  Morné J Vorster; Brian W Allwood; Andreas H Diacon; Coenraad F N Koegelenberg
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

3.  Diagnostic value of sputum adenosine deaminase (ADA) level in pulmonary tuberculosis.

Authors:  Fariba Binesh; Hadi Jalali; Mohammad Reza Zare; Farhad Behravan; Arefeh Dehghani Tafti; Fatemah Behnaz; Mohammad Tabatabaee; Seyed Hossein Shahcheraghi
Journal:  Germs       Date:  2016-06-01

4.  Serum adenosine deaminase activity in patients with systemic lupus erythematosus: a study based on ADA1 and ADA2 isoenzymes pattern.

Authors:  Reza Saghiri; Niloufar Ghashghai; Shafieh Movaseghi; Pegah Poursharifi; Shohreh Jalilfar; Manijeh Ahmadi Bidhendi; Leila Ghazizadeh; Mina Ebrahimi-Rad
Journal:  Rheumatol Int       Date:  2011-02-25       Impact factor: 2.631

5.  Gamma interferon immunospot assay of pleural effusion mononuclear cells for diagnosis of tuberculous pleurisy.

Authors:  Mingfeng Liao; Qianting Yang; Jieyun Zhang; Mingxia Zhang; Qunyi Deng; Haiying Liu; Michael W Graner; Hardy Kornfeld; Boping Zhou; Xinchun Chen
Journal:  Clin Vaccine Immunol       Date:  2014-01-03

6.  Differential diagnosis of tuberculous and malignant pleural effusions: what is the role of adenosine deaminase?

Authors:  Bojan Zarić; Vesna Kuruc; Aleksandar Milovančev; Marica Markovic; Tatjana Šarčev; Vukašin Čanak; Slobodan Pavlović
Journal:  Lung       Date:  2008-03-21       Impact factor: 2.584

7.  Adjustments of serum lactate dehydrogenase isoenzymes and their significance in monitoring the treatment in patients with tubercular pyothorax.

Authors:  Riaz Ahmad; Mumtaz Alam; M Faisal Siddiqui; Absar-Ul Hasnain
Journal:  Indian J Clin Biochem       Date:  2008-06-11

8.  Sensitivity, specificity, negative and positive predictive values of adenosine deaminase in patients of tubercular and non-tubercular serosal effusion in India.

Authors:  Bharat Kumar Gupta; Vinay Bharat; Debapriya Bandyopadhyay
Journal:  J Clin Med Res       Date:  2010-05-19

9.  ACE/ACE2 ratio and MMP-9 activity as potential biomarkers in tuberculous pleural effusions.

Authors:  Wen-Yeh Hsieh; Tang-Ching Kuan; Kun-Shan Cheng; Yan-Chiou Liao; Mu-Yuan Chen; Pei-Heng Lin; Yuan-Chang Hsu; Chen-Yi Huang; Wei-Hua Hsu; Sheng-Yao Yu; Chih-Sheng Lin
Journal:  Int J Biol Sci       Date:  2012-10-17       Impact factor: 6.580

10.  Diagnostic value of pleural fluid interferon-gamma and adenosine deaminase in patients with pleural tuberculosis in Qatar.

Authors:  Fahmi Yousef Khan; Maha Hamza; Aisha Hussein Omran; Muhannad Saleh; Mona Lingawi; Adel Alnaqdy; Mohamed Osman Abdel Rahman; Hasan Syed Ahmedullah; Alan Hamza; Ahmed Al Ani; Mehdi Errayes; Mona Almaslamani; Ahmed Ali Mahmood
Journal:  Int J Gen Med       Date:  2013-01-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.